UK authority warns of Dupixent adverse effects
Medicines and Healthcare products Regulatory Agency says the atopic dermatitis from Regeneron and Sanofi can cause eye reactions.
by christian bundgaard, translated by daniel pedersen
Regeneron and Sanofi’s atopic dermatitis treatment, the blockbuster Dupixent (dupilumab), has gotten unwanted attention by the UK Medicines and Healthcare products Regulatory Agency (MHRA). On Tuesday, as reported by industry media Endpoints News, the authority warned of new and serious eye reactions from using the drug.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Dupixent might halt "the atopic march," research finds
For subscribers
Leo Pharma's label extension wish granted
For subscribers
